A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia

Voruciclib blocks a molecule called cyclin-dependent Kinase (CDK), which then decreases the amount of another molecule, called myeloid cell leukemia protein 1 (Mcl-1). Mcl-1 shows up in large amounts in B cell type cancers. It is thought that blocking Mcl-1may stop the growth of B cell type cancers or enable other drugs to work more effectively.